Janssen gets expanded authorization for Genmab's Darzalex in EU

On Tuesday, the EU Commission approved Genmab's Darzalex for treating the rare disease light-chain amyloidosis.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Genmab's collaborative partner Janssen has received a European marketing Authorization for Darzalex for treating the rare disease Light-chain (AL) amyloidosis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading